FDA and EMA report on effect of incretin mimetics on Pancreatitis and Pancreatic Cancer
The FDA and EMA review published in NEJM has found little evidence that incretin mimetic drugs cause Pancreatitis or Pancreatic Cancer thus giving reassurance to patients and to the manufacturers of Victoza, Onglyza, Nesina, Tradjenta, Byetta, Bydureon and Januvia/Janumet. See - "Pancreatic Safety of Incretin-Based Drugs � FDA and EMA Assessment."- Amy G. Egan, M.D., M.P.H., Eberhard Blind, M.D., Ph.D., Kristina Dunder, M.D., Pieter A. de Graeff, M.D., B. Timothy Hummer, Ph.D., Todd Bourcier, Ph.D., and Curtis Rosebraugh, M.D., M.P.H.-N Engl J Med 2014; 370:794-797 February 27, 2014DOI: 10.1056/NEJMp1314078.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.